Quantcast
Last updated on April 23, 2014 at 11:40 EDT

MiMedx to meet with FDA on October 28th

October 17, 2013

MARIETTA, Ga., Oct. 17, 2013 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that the Food and Drug Administration (“FDA”) has rescheduled its meeting with the Company to take place on October 28, 2013. This meeting to discuss the recent Untitled Letter MiMedx received from the FDA was initially scheduled for October 16, 2013, but was postponed due to the recent partial Federal Government shutdown.

Parker H. Petit, Chairman and CEO, said, “We appreciate how quickly the FDA has set the rescheduled meeting date. We look forward to the meeting on October 28(th) to further clarify our position and understand the FDA’s issues of concern. We are anxious to discuss our position on this matter, and we appreciate the agency working with us to reschedule this meeting so timely.”

About MiMedx

MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. “Innovations in Regenerative Biomaterials” is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® process, to produce a safe, effective and minimally manipulated implant for homologous use. MiMedx® is the leading supplier of amniotic tissue, having supplied over 190,000 allografts to date to distributors and OEMs for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

Safe Harbor Statement

This press release includes statements that look forward in time or that express management’s beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to the Company’s goal of gaining insight into the FDA’s issues and concerns, and the prospect for resolving this issue. These statements are based on current information and belief, and are not guarantees of future performance. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the issues raised by the FDA are not timely or favorably resolved, that the Company is unable to sell its micronized product under the current regulatory pathway, and the risk factors detailed from time to time in the Company’s periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2012, and its most recent Form 10-Q. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company’s disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.

SOURCE MiMedx Group, Inc.


Source: PR Newswire